Canagliflozin (hemihydrate): SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a high-purity small molecule SGLT2 inhibitor supplied by APExBIO for metabolic and diabetes mellitus research (product page). It blocks renal glucose reabsorption at the SGLT2 transporter, supporting studies of glucose homeostasis pathways (Breen et al. 2025). Canagliflozin (hemihydrate) demonstrates no significant mTOR inhibitory activity, clarifying its pathway specificity. Its solubility profile (≥40.2 mg/mL in ethanol, ≥83.4 mg/mL in DMSO) and high purity (≥98%, HPLC/NMR) suit in vitro and in vivo research. This article updates prior reviews by integrating recent benchmarks, clarifying misconceptions, and providing workflow-ready recommendations.

Biological Rationale

Type 2 diabetes mellitus and metabolic syndrome are characterized by impaired glucose homeostasis. Sodium-glucose co-transporter 2 (SGLT2) mediates the majority (approximately 90%) of renal glucose reabsorption from the proximal tubule (PMID: 32030717). Pharmacological inhibition of SGLT2 increases urinary glucose excretion, reducing blood glucose. Canagliflozin (hemihydrate), a research-grade small molecule, is used to study these processes with high selectivity for SGLT2 versus SGLT1. Its chemical stability and well-characterized mechanism make it a gold standard for glucose metabolism research (APExBIO).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) binds the SGLT2 protein in the renal proximal tubule, competitively inhibiting glucose reabsorption (PMID: 32030717). This results in increased urinary glucose excretion and reduction in fasting and post-prandial blood glucose levels. The compound exhibits high selectivity for SGLT2 (IC₅₀ ≈ 2 nM) over SGLT1 (IC₅₀ ≈ 710 nM), minimizing off-target effects (APExBIO datasheet). Its mechanism is independent of insulin secretion or sensitivity, making it relevant in insulin-independent diabetes models. Notably, recent studies confirm that canagliflozin does not inhibit mTOR or TOR signaling pathways in yeast or mammalian systems (Breen et al. 2025).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) at ≥98% purity is confirmed by HPLC and NMR; stability is maintained at -20°C with blue ice shipping (APExBIO C6434 datasheet).
• Demonstrates water insolubility but dissolves in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), supporting diverse assay platforms (APExBIO).
• Specifically inhibits SGLT2-mediated glucose reabsorption in renal proximal tubules; does not affect SGLT1 at research-relevant concentrations (PMID: 32030717).
• Does not inhibit TOR/mTOR pathways at concentrations up to 100 μM in yeast-based drug sensitivity models (Breen et al. 2025).
• Supports glucose homeostasis studies in metabolic disorder and diabetes mellitus models (see comparative analysis).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is a core reagent for diabetes mellitus research, glucose metabolism studies, and metabolic disorder models. Its specificity enables clear attribution of phenotypic outcomes to SGLT2 inhibition. However, it is not a suitable tool for mTOR/TOR pathway studies, as confirmed by recent drug-sensitized yeast assays (Breen et al. 2025). For researchers seeking mTOR inhibitors, validated alternatives include rapamycin, Torin1, and AZD8055.

• Canagliflozin (hemihydrate): Beyond SGLT2 Inhibition in Advanced Research – This article explores integration with metabolic signaling pathways; our review clarifies its lack of mTOR activity.
• Canagliflozin Hemihydrate: Unraveling SGLT2 Inhibition Beyond mTOR – While providing a systems-level comparison, this article is extended here by direct recent mTOR pathway evidence.
• Canagliflozin Hemihydrate: Pathway-Specific SGLT2 Inhibitor in Diabetes Research – We update its mechanistic selectivity using 2025 peer-reviewed findings.

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) is not an mTOR or TOR inhibitor at concentrations up to 100 μM (Breen et al. 2025).
• It is not intended for diagnostic or clinical use; for research use only (APExBIO).
• Solutions of Canagliflozin (hemihydrate) are not stable for long-term storage and should be freshly prepared before use.
• It does not modulate insulin secretion or sensitivity directly; primary effect is SGLT2 inhibition.
• Water insolubility requires solubilization in ethanol or DMSO for experimental use.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) is supplied as a solid compound with ≥98% purity (C6434, APExBIO). Recommended storage is at -20°C; shipping occurs with blue ice to maintain integrity. For in vitro use, dissolve in DMSO (≥83.4 mg/mL) or ethanol (≥40.2 mg/mL); avoid water as a solvent. Prepare working solutions fresh and use promptly. Typical research concentrations range from 10 nM to 10 μM for SGLT2 inhibition assays. For in vivo work, refer to the literature for species-specific dosing and formulation protocols.

Conclusion & Outlook

Canagliflozin (hemihydrate) remains a validated SGLT2 inhibitor for metabolic and diabetes research, with a clear mechanism and robust purity profile (APExBIO). Its lack of mTOR pathway inhibition is now definitively established, supporting its use in pathway-specific studies. Future research may explore combinatorial metabolic interventions or deeper characterization of SGLT2's role in non-renal tissues. For further reading, see comparative analyses and protocol updates in the referenced internal articles.